Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline - - Interim Phase 1b proof-of-concept data, including initial efficacy ...

Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

Naturally, the streaming service has stayed close-clipped on specific plot developments, but a recent teaser trailer has similarly eschewed subtlety (with a voiceover from June) while promising to ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks. Gilead has joined Johnson & Johnson JNJ, and a cluster ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

GILD opened at $116.04 on Wednesday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 52-week low of $62.07 and a 52-week ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00. The company’s shares closed yesterday at $114.74.